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Abstract
During normal cerebellar development, the remarkable expansion of granule cell progenitors (GCPs) generates a
population of granule neurons that outnumbers the total neuronal population of the cerebral cortex, and provides a
model for identifying signaling pathways that may be defective in medulloblastoma. While many studies focus on
identifying pathways that promote growth of GCPs, a critical unanswered question concerns the identification of
signaling pathways that block mitogenic stimulation and induce early steps in differentiation. Here we identify WNT3
as a novel suppressor of GCP proliferation during cerebellar development and an inhibitor of medulloblastoma
growth in mice. WNT3, produced in early postnatal cerebellum, inhibits GCP proliferation by down-regulating pro-
proliferative target genes of the mitogen Sonic Hedgehog (SHH) and the bHLH transcription factor Atoh1. WNT3
suppresses GCP growth through a non-canonical Wnt signaling pathway, activating prototypic mitogen-activated
protein kinases (MAPKs), the Ras-dependent extracellular-signal-regulated kinases 1/2 (ERK1/2) and ERK5, instead
of the classical β-catenin pathway. Inhibition of MAPK activity using a MAPK kinase (MEK) inhibitor reversed the
inhibitory effect of WNT3 on GCP proliferation. Importantly, WNT3 inhibits proliferation of medulloblastoma tumor
growth in mouse models by a similar mechanism. Thus, the present study suggests a novel role for WNT3 as a
regulator of neurogenesis and repressor of neural tumors.
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Introduction
During normal cerebellar development, the extraordinary
amplification of granule cell progenitors (GCPs) generates vast
numbers of granule neurons, up to 45 billion in the human
cerebellum. This unique postnatal expansion of neuronal
precursors is driven in large part by the mitogen Sonic
Hedgehog (SHH) [1], and deregulation of the SHH signaling
pathway in GCPs gives rise to a subset of medulloblastoma
[2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24],
which is the most prevalent metastatic brain tumor of childhood
[5,8]. Thus, GCP proliferation provides a model for normal CNS
neurogenesis and for identifying signaling pathways pertinent
to this devastating disease [8]. To date, studies on GCP
proliferation have mainly focused on SHH and its receptor,
Patched (PTCH1) [1,24]; JAG1 and its receptor, NOTCH2, [25];
Trp53 and the cyclin-dependent kinase (CDK) inhibitor p18Ink4/
Cdkn2c [26]; and Mycn and the D-type cyclins [27,28].
However, a critical unanswered question concerns the
identification of signaling pathways that block mitogenic
stimulation and induce early steps in differentiation, and as
such may offer insight into potential treatments for
medulloblastoma.
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Initially described in Drosophila, murine WNT proteins are a
large family (>19) of highly conserved secreted signaling
molecules that regulate cell-cell interactions during the
development of multiple organ systems, including the CNS.
WNT proteins regulate diverse cellular processes, including
proliferation, cell fate determination, differentiation, axon
growth and synapse formation [29]. With regard to cerebellar
development, Wnt1 is required to induce the isthmus organizer,
which establishes the midbrain/hindbrain boundary to specify
the cerebellar territory [30,31,32,33]. Deregulation of WNT
signaling components in early Nestin-expressing progenitors
and GCPs impairs proliferation and causes premature
differentiation, resulting in cerebellar abnormalities [34,35,36].
At later stages of cerebellar development, WNT7a functions in
the terminal differentiation of cerebellar granule neurons,
remodeling axons and growth cones of mossy fiber afferents as
they form synaptic connections with granule neuron dendrites
[37,38,39,40]. Although aberrant WNT signaling affects
proliferation and has been implicated in medulloblastoma
[3,4,5,9,41,42,43,44,45,46,47,48,49,50], this subset of
medulloblastomas is thought to arise outside of the cerebellum
from progenitors in the dorsal brainstem [45].
Most studies have focused on the role of canonical, β-
catenin-dependent, WNT signaling in development. Canonical
WNT signaling stabilizes β-catenin, which forms complexes
with TCF/LEF transcription factors and controls the expression
of many genes important for CNS neurogenesis, including
Mycn, cyclin D1 (Ccnd1), neurotrophin 3 (Ntf3), connexin-43
(Gja1) and metalloproteases (Mmps) [29,51,52]. Non-canonical
WNT signaling, which functions in a β-catenin-independent
manner, is less well understood. Non-canonical pathways
include WNT/PCP (planar cell polarity) signaling, the WNT/Ca2+
pathway and the WNT/Jun N-terminal kinase (JNK) pathway
[53,54,55,56,57,58]. While some WNTs seem to preferentially
signal through a canonical or non-canonical pathway, the
activity of WNTs and their effects on cell growth and
development depend on the cellular context and the receptors
involved [59]. Although studies have identified a role for
downstream signaling components of canonical WNT signaling
in early GCP development, which particular WNTs regulate
postnatal GCP proliferation and differentiation, as well as the
signaling pathways they utilize, remain to be defined.
Here we examined the role of WNT3 in GCP proliferation
and medulloblastoma growth. We provide evidence that WNT3
inhibits GCP proliferation in vitro and ex vivo. WNT3 attenuates
GCP growth by inhibiting pro-proliferative SHH-induced
transcriptional responses and the bHLH transcription factor
Atoh1 [60]. WNT3 acts through a non-canonical WNT signaling
pathway that involves phosphorylation of prototypic mitogen-
activated protein kinases (MAPKs), the Ras-dependent
extracellular-signal-regulated kinases 1/2 (ERK1/2) and ERK5.
Importantly, WNT3 inhibits proliferation of medulloblastoma
tumor growth in mouse models by a similar mechanism. Thus,
WNT3 is a novel growth suppressor during cerebellar
development and an important regulator of medulloblastoma
formation.
Materials and Methods
Ethics statement
All animal work was performed as required by the United
States Animal Welfare Act and the National Institutes of
Health's policy to ensure proper care and use of laboratory
animals for research. Mice were housed in accredited facilities
of the Association for Assessment of Laboratory Animal Care
(AALAC) in accordance with the National Institutes of Health
guidelines.
All animal work conducted to obtain primary GCPs was
performed under established guidelines and supervision by the
Institutional Animal Care and Use Committee (IACUC) of The
Rockefeller University under protocol number 1009. All efforts
were made to minimize suffering. Euthanasia of neonatal
mouse pups was carried out by reducing their core body
temperature, by placing them in the refrigerator (4°C) for
approximately ten minutes, followed by decapitation. Chilling
early postnatal mouse pups is known to be a painless and fully
reversible method for inducing "anesthesia", and is preferable
to the use of anesthetic overdose in neonates because it is
painless and avoids any compromise to the experiments that
drugs might cause.
All animal work conducted to obtain primary
medulloblastoma cells was performed under established
guidelines and supervision by the St. Jude Children's Research
Hospital's Institutional Animal Care and Use Committee
(IACUC) permit number A3077-01, that approved all
procedures in this study as required by the United States
Animal Welfare Act and the National Institutes of Health's
policy to ensure proper care and use of laboratory animals for
research under the protocol 378. All surgery was performed
under sodium pentobarbital anesthesia, and all efforts were
made to minimize suffering, including the administration of
analgesics when necessary. Mice were monitored daily
because we knew that the animals would get tumors, and mice
that developed medulloblastoma tumors were humanely
euthanized using CO2 once we detected signs of sickness,
including failure to thrive, head dome, and gait problems.
GCPs culture
Granule cell progenitors (GCPs) were purified from P6
C57Bl6/J mice (Jackson Laboratory, Bar Harbor, ME), by
Percoll gradient sedimentation and pre-plating, as described
previously [61]. The purity of GCPs was greater than 98%.
Briefly, purified GCPs were re-suspended in serum-free
medium (DMEM/F12, 1.5% Glucose, 0.1% Na bicarbonate, 5
mM Hepes, 20 mM Glutamine, 1% N2). In some experiments,
cells were grown on Poly-D-Lysine (PDL, 10 µg/ml, Sigma),
MATRIGEL (Beckton Dickson, Growth Factor Reduced, 0.2
mg/ml) or laminin (10 µg/ml, Invitrogen) coated dishes. For
immunoblotting analysis, 3.75x106 GCPs/ml in serum-free
media were plated in 6 well dishes and cultured for 24 h. Cells
were treated with WNT3 conditioned medium (100 ng/ml),
commercially available WNT3 (250 ng/ml, Creative Biomart),
BMP7 (200 ng/ml, R&D), SHH (3 µg/ml, R&D), 6-
bromoindirubin-3’-oxime (BIO, 5 µM), Cyclohexamide (10
µg/ml, Sigma), PD98059 (50 µM, Cell Signaling), CHIR99021
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(3 µM, StemGent) or LiCl (10 nM) for 24 h, unless otherwise
noted. Afterwards, GCPs were lysed with TRIS buffer
containing Triton X-100 (50 mM Tris-HCl pH 7.5, 100 mM
NaCl, 50 mM NaF, 5 mM EDTA, 1% Triton X-100, 40 mM β
glycerophosphate, 200 µM sodium orthovanadate, 100 mM
PMSF and protease inhibitor cocktail (Roche). Western blots
were performed a minimum of three times, and a
representative image is shown.
Quantitative PCR
Quantitative PCR experiments were subjected to all
“essential” qPCR publishing criteria based on the
recommendations of the MIQE guidelines report [62]. All
primers used for final experiments were tested on gradient
PCR for annealing temperature and single product
amplification. Primer efficiency, determined by standard curve
using cDNA, was between 1.95 and 2.05. Melt curve analysis
showed a single well-defined peak at the predicted melting
temperature for each product. Both no template and reverse
transcriptase negative controls showed no amplification.
Primers are listed in Table S1.
For analysis of WNT and SHH signaling components in
Figure 1A and Figure S5 for each developmental stage (P5 to
adult; adult is defined as P55 or older), cerebellar tissue was
removed, snap frozen with liquid nitrogen and stored at -80°C.
RNA was extracted from the frozen tissue with a Teflon-glass
homogenizer using TriZol reagent (Ambion). RNA quantity was
assayed using a Nanodrop (Thermo Scientific). For each
sample, an equal amount of RNA was digested with DNAse I
(Invitrogen) and then concentrated and purified using a column
purification kit (Qiagen RNeasy). Bioanalysis (Agilent 2100)
showed negligible levels of ethanol, DNA or protein in the
samples with RNA integrity (RIN) >9 for all samples used. RNA
samples were then reverse transcribed to cDNA using random
hexamers and oligo DT primers (Roche Transcriptor). We used
a geometric averaging protocol to normalize gene expression
against three control genes: beta-2-microglobulin (B2M),
hyporanthine-guanine phosphoribosyltransferase (HPRT1) and
ribosomal subunit 18s (M18s) [63,64]. Results were analyzed
on a Roche LC 480 II system using Roche LC 480 software.
For the analysis of SHH target genes in the presence and
absence of WNT3 in Figure 2D, GCPs were treated with
conditioned medium or WNT3 for 6 h before isolating RNA. For
the analysis of SHH target genes in the presence and absence
of WNT3 and SHH in Figure 2E, GCPs were treated with SHH
for 24 h, and control medium or WNT3 was added during the
last 6 h before isolating RNA. For the GLI1 overexpression
experiment in Figure 2F, GCPs were electroporated with a
control vector or pSR-Gli1 vector [65] and treated with control
medium or WNT3 for 24 h. For the analysis of SHH target
genes in the presence and absence of WNT3 and SHH in
Figure 2D,E and the GLI1 overexpression experiment in Figure
2F, RNA was prepared using TRiZol reagent (Ambion). cDNA
was synthesized using the SuperScript First-Strand Synthesis
System, and qPCR assays were performed using iTaq SYBR
Green Supermix with ROX (Bio-Rad). β-actin was used as an
internal control. qPCR results for the experiments shown in
Figures 2D,E and 2F were analyzed with a MyiQ single color
real-time PCR detection system (Bio-Rad).
Expression constructs, retrovirus and WNT3
production
Full-length mouse Wnt3 cDNA was amplified from RNA
prepared from P6 cerebellum using the following primers:
(Forward/EcoRI) 5’-GGAATTCTCGGCGCTGCTTCTAATG-3’
and (Reverse/HpaI) 5’-
GGTTAACCCCTTCCCAGTGCCCTGG-3’, and inserted into
the pCXi expression vector by EcoRI/HpaI. We stably infected
NIH3T3 cells with the retroviral vector pCxi containing Wnt3
cDNA, cultured the cells 5 days in 0.5% calf serum, BME, and
pen/strep and collected the medium.
WNT3 protein is 39 kDa. To produce WNT3 conditioned
medium, 400 ml of control or WNT3 supernatant were filtered
using four 50 kDa MWCO PES Sartorius Vivacell 100 ml ultra
centrifuge filters to remove proteins larger than 50 kDa. The
eluate (approximately 360 ml total) was then concentrated
using four 10 kDa MWCO PES Sartorius Vivacell 100 ml ultra
centrifuge filters to a top fraction volume of 10 ml each (40 ml
total) to remove proteins smaller than 10 kDa. The 40 ml of
concentrated 10 kDa top fraction was then further concentrated
using four 15 ml Amicon Ultra Ultracel 10K centrifugal filters, to
a final volume of 1 ml per filter (4 ml total). The resulting 4 ml of
100x concentrated supernatant was dialyzed in Slide-A-Lyzer
dialysis cassettes (Pierce, MW 7000) in BME medium at 4°C
overnight. Contamination by other WNTs (WNT1, 3a, 5a, 7a)
was excluded by immunoblotting control and WNT3
conditioned medium for these WNT proteins, and extensive
tests were performed to rule out the presence of other growth
factors (data not shown). WNT3 conditioned medium will
therefore be referred to as “WNT3” and control conditioned
medium referred to as “control”.
Virus production and infection using the pMSCV-Atoh1-
IRES-GFP vector were performed as described previously [66].
Antibodies
The following primary antibodies were used for either
immunocytochemistry or Western blot analysis: anti-WNT3
(mouse, Invitrogen), anti-GFAP (mouse, Dako), anti-Calbindin
(rabbit, Swant), anti-β-catenin (rabbit, Cell Signaling), anti-
active-β-catenin (mouse, Upstate Biotechnology), anti-
phospho-Y216-GSK3β and anti-GSK3β (mouse, BD
Transduction), anti-MYCN (rabbit, C-19, Santa Cruz), anti-
phospho-p38 (rabbit, Cell Signaling), anti-p38 (rabbit, Abcam),
anti-phospho-JNK (mouse, Cell Signaling) and anti-JNK (rabbit,
Cell Signaling), anti-phospho-ERK1/2 and anti-ERK1/2 (rabbit,
Cell Signaling), anti-phospho-ERK5 and anti-ERK5 (rabbit, Cell
Signaling), anti-Pax6 (rabbit, Covance) anti-phospho-AKT
(rabbit, Cell Signaling), anti-Cyclin D1 (mouse, Santa Cruz) and
anti-GAPDH (mouse, Chemicon), anti-phospho-Smad 1/5/8
(rabbit, Cell Signaling), anti-Smad1 (rabbit, Dr. J. Massague),
and anti-β-actin (mouse, MP Biomedicals). Secondary
antibodies used (Molecular Probes) included goat anti-rabbit
IgG-Alexa 488 Fluor, goat anti-rabbit IgG-Alexa 555 Fluor, goat
anti-mouse IgG-Alexa 488 Fluor, and goat anti-mouse IgG-
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Figure 1.  Gene expression profile of Wnts in cerebellar development.  (A) qPCR of Wnt3, Wnt4, Wnt5a, Wnt5b, Wnt7a, and
Wnt10b, in the mouse cerebellum from postnatal day 5 (P5) to adult. Wnt levels were normalized against β-2-microglobulin (B2M),
hyporanthine-guanine phosphoribosyltransferase (HPRT1) and ribosomal subunit 18s (M18s). (B) WNT3 protein levels during
cerebellar development. Immunoblotting of cerebellar lysates from P0 to P56 (adult) with an anti-WNT3 antibody showed an
increase in WNT3 protein during cerebellar development.
doi: 10.1371/journal.pone.0081769.g001
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Alexa 555 Fluor (all used at 1:500). DRAQ5 was used at
1/1000 (647 nm excitation, BioStatus).
[3H]-Thymidine incorporation assay
To assay [3H]-Thymidine incorporation, we plated purified P6
cerebellar GCPs (300,000 cells per well) in 96-well dishes and
treated them with WNT3, SHH or other proteins or inhibitors for
24 h. WNT3 was used at 100 ng/ml, SHH (R&D) at 3 µg/ml,
BMP2 (R&D) at 150 ng/ml, BMP4 (R&D) at 100 ng/ml, BMP6
(R&D) at 150 ng/ml, BMP7 (R&D) at 200 ng/ml, Noggin (R&D)
at 1 µg/ml and PD98059 (Cell Signaling) at 50 µM. 1 µCi of
[methyl-3H]-thymidine (Amersham and MP Biomedicals, LLC)
was added to each well after 1 day in vitro (DIV) and the cells
were harvested and analyzed using TOP-Count (Perkin Elmer).
Terminal Deoxyuridine Nick End-Labeling (TUNEL)
To assay apoptosis, purified GCPs were plated at 2x106
cells/cm2 in serum-free medium onto plates coated with PDL
Figure 2.  WNT3 decreases GCP proliferation by inhibiting SHH dependent gene transcription.  (A) WNT3 decreased
proliferation of GCPs by 40.3± 5.0% of the control (Con) (n=3) as measured by [3H]-Thymidine incorporation assay. (B) WNT3 did
not increase cell death of GCPs in a TUNEL assay at 2 DIV (Con, 12.5±1.6%; WNT3, 13.1±0.7% (n=3)). (C) WNT3 decreased SHH
dependent proliferation of GCPs (Con & SHH, 354.8±18.7%; WNT3 & SHH, 232.9±28.7% (n=3)). (D) WNT3 decreased Gli1, and
Ptch1 mRNA levels after 6 h of treatment (Con=1; WNT3: Gli1=0.56±0.10, Gli2=0.90±0.10, Mycn= 0.99±0.05, Ptch1=0.58±0.09,
and Ccnd1=0.89±0.09). (E) Treatment of GCPs with WNT3 antagonized the transcription of SHH targets. SHH was added for 24 h
and WNT3 was added for 6h. (SHH/Con=1; SHH/WNT3: Gli1=0.62±0.04, Gli2=0.75±0.02, Mycn=1.12±0.05, Ptch1=0.70±0.11 and
Ccnd1 =1.03±0.12.). (F) After 24 h of GLI1 overexpression in GCPs, Gli2, and Ptch1 mRNA levels increase in the control condition
(Gli1=464±119, Gli2=2.04±0.25, Ptch1=1.59±0.14) and this effect is inhibited in the presence of WNT3 (Gli1=314±166,
Gli2=1.14±0.3, Ptch1=0.71±0.12). Data represent the mean ± s.e.m.: *p<0.05, **p<0.01, ***p<0.001. NS, not significant.
doi: 10.1371/journal.pone.0081769.g002
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and MATRIGEL for 2 days, and TUNEL reaction was
performed as described by the manufacturer. Confocal images
of DRAQ5 and TUNEL stained cells were acquired with a
Radiance 2000 confocal laser-scanning microscope (Bio-Rad),
and labeled cells were counted using MetaMorph software
(Image One).
Organotypic slice culture and immunocytochemistry
250 µm sagittal slices of cerebellar cortex were made from
P7 mice using a vibratome (Leica VT 1000S) [67,68] and
treated with WNT3 (100 ng/ml) or control supernatant for 24 h.
For immunocytochemistry, organotypic slice cultures were fixed
with 4% paraformaldehyde, incubated in 20% sucrose for 24 h,
and embedded in OCT (Tissue Tek). Cryostat sections (16 µm)
were generated with a Leica CM30505 cryostat, after which
sections were permeabilized in 0.5% Triton X-100/PBS,
blocked in 10% normal goat serum/PBS and immunostained
with primary and secondary antibodies as described above.
Confocal images were acquired with a Radiance 2000 confocal
laser-scanning microscope (Bio-Rad).
Luciferase reporter assay
The luciferase vectors we used included a Firefly luciferase
plasmid controlled by the TCF/LEF promoter (pTOP-flash) to
study Wnt-β-catenin signaling pathway, a Firefly luciferase
plasmid (SRE) driven by a minimal MAPK promoter plus
multiple SRE binding sites to test MAPK signaling pathway,
and a Renilla luciferase vector driven by the TK promoter (pRL-
TK) to normalize the results of Firefly luciferase activity assays.
The vectors were electroporated into 5x106 purified GCPs,
using the Amaxa mouse neuron nucleofection kit (Amaxa
Biosystems). The transfection included 1 µg of SRE-Firefly-
luciferase vector and 75 ng of Renilla-TK vector (Stratagene).
1x106 cells were then plated in 96 well dishes, and when
indicated, WNT3 was added at 100 ng/ml, SHH (R&D) at 3
μg/ml, BDNF (R&D) at 10 ng/ml and PD98059 (Cell Signaling)
at 50 μM for 24 h post-transfection. To measure the luciferase
activity, cells were lysed and the luciferase assay was
performed with the Dual-Luciferase Reporter Assay (Promega)
as described by the manufacturer.
Culture of mouse medulloblastoma cells in vitro.  To
make sure that the loss of p53 did not affect the response of
tumor cells to WNT3 treatment, tumor cells were purified by
Percoll density gradients from medulloblastomas that
spontaneously arose from two tumor-predisposed genetically
engineered mouse models of SHH medulloblastoma, Ink4c-/-,
p53Fl/-, Nestin-Cre+ and Ink4c-/-, Ptch1+/- [23]. Tumor cells
were grown on PDL and MATRIGEL coated plates in
Neurobasal medium with B27, N2, 2mM glutamine, Pen/Strep
(Invitrogen), 4 mg/ml BSA, and 0.45% D-Glucose.
Cyclopamine was used at 10 μM (LC laboratories), in the
presence or absence of 100 ng/ml of WNT3 supernatant.
Propagation of flank allografts.  Medulloblastoma cells
were purified by Percoll density gradient from five independent
primary tumors that spontaneously arose from Ink4c-/-, p53Fl/-,
Nestin-Cre+ mice. Tumor cells purified from each tumor were
pooled and infected with MSCV-based retroviruses either
expressing only the yellow fluorescent protein (YFP) from an
internal ribosomal entry site or co-expressing WNT3 and YFP.
0.5 x 106 infected cells were either directly subcutaneously
transplanted into the flank of six naïve recipient nude mice or
FACS sorted for YFP positive cells before transplant into the
flank of four recipient nude mice (2 mice per tumor). Secondary
allograft flank tumors were analyzed 3 weeks later by weight
and for YFP expression. To control for variability, flank
injections of YFP only marked tumor cells was done on the
right side while tumor cells expressing WNT3 and YFP were
transplanted on the left flank of each recipient mouse.
Flow cytometry, cell cycle and apoptosis analyses
YFP expression and DNA content were measured by
fluorescent activated cell sorting (FACS), while apoptosis was
analyzed by staining with Annexin-V antibody (Roche).
Statistical analysis
Data were presented as mean ± s.e.m. from at least three
independent experiments. Direct comparisons were made
using Student’s t-test and multiple group comparisons were
made using one-way analysis of variance (ANOVA). Statistical
significance was defined as P < 0.05, 0.01 or 0.001 (indicated
as *, ** or ***, respectively). P values ≥ 0.05 were considered
not significant.
Results
WNT3 decreases proliferation and promotes
differentiation of GCPs
To investigate the role of the Wnts in cerebellar
development, we assayed the expression of ten Wnt family
members, Wnt1, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6,
Wnt7a, Wnt8b and Wnt10b, in the mouse cerebellum from
postnatal day 5 (P5) to adult by quantitative PCR (qPCR).
These assays revealed expression of Wnt3, Wnt4, Wnt5a,
Wnt5b, Wnt7a, and Wnt10b mRNA transcripts during
cerebellar development, whereas Wnt1, Wnt3a, Wnt6 and
Wnt8b transcripts were not detected (Figure 1A). Of the WNTs
expressed during cerebellar development, only Wnt3 and
Wnt7a levels increased postnatally into adulthood, at a time
when GCPs exit the cell cycle, differentiate and mature. As
WNT7a has been characterized extensively, with prior
experiments demonstrating a role for WNT7a in synapse
formation [37,38,39,40], we focused on the role of WNT3 in
GCP development. Note that WNT3 protein levels also
increased postnatally (Figure 1B).
In order to test the effects of WNT3 on purified GCPs in vitro
or on GCPs in organotypic slice preparations, we prepared
enriched WNT3 from conditioned medium. WNT proteins are
lipid-modified glycoproteins that need to be solubilized in
medium containing hydrophobic carriers for optimal activity,
and using conditioned medium is a classical approach for
testing WNT function [38,69]. To produce WNT3, we stably
infected NIH3T3 cells with the retroviral vector pCXi containing
Wnt3 cDNA that expresses the secreted WNT3 protein. A pCXi
control vector was also transfected into NIH3T3 cells to obtain
control conditioned medium. Enriched WNT3 was analyzed by
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immunoblotting for WNT3 expression (Figure S1A), and the
concentration of WNT3 in the conditioned medium was
estimated at 1 µg/ml (data not shown). Since the concentration
of WNT3 in early postnatal cerebellum was estimated at 100
ng/ml by immunoblotting cerebellar lysates for WNT3
expression (unpublished data), we treated purified GCPs and
cerebellar slices with 100 ng/ml of WNT3, and the same
volume of control medium was used for comparison.
The addition of WNT3 to cultures of GCPs purified from P6
cerebella for 24 h inhibited cell proliferation, measured by [3H]-
Thymidine incorporation, by approximately 40% relative to
control cells (Figure 2A), which was similar in degree to that of
BMP treatment of GCPs (Figure 4A). We also tested newly
commercially available recombinant WNT3 in our growth assay
and found that this recombinant WNT3 also decreased GCP
proliferation (Figure S4A). TUNEL assays did not reveal a
significant difference in the percentage of apoptotic cells
between control and WNT3-treated cultures, suggesting that
changes in cell number we observed after treatment with
WNT3 did not relate to cell death (Figure 2B).
As SHH drives the proliferation of GCPs during postnatal
cerebellar development [1], we examined whether WNT3 can
antagonize the mitogenic effect of SHH by treating purified
GCPs with SHH (3 µg/ml) or with both WNT3 and SHH (Figure
2C). The results of these experiments showed that treatment
with WNT3 significantly reduced SHH-induced GCP [3H]-
Figure 4.  GCP proliferation induced by WNT3 is not dependent on the BMP pathway.  (A) WNT3 and BMPs (BMP2, BMP4,
BMP6, and BMP7) cooperated to decrease proliferation of GCPs as measured by [3H]-Thymidine incorporation assay. (B) The BMP
inhibitor Noggin did not affect the WNT3-mediated decrease in proliferation. (WNT3, 59.9±4.6% of the control value; Con/Noggin,
93.5±1.7%; and WNT3/Noggin 46.4±2.9% (n=3).) (C) GCPs were stimulated for 4h at 1 DIV with WNT3 or BMP7 and analyzed by
immunoblotting with the anti-phospho-SMAD1/5/8 antibody. The anti-SMAD1 antibody was used for normalization to obtain the
percentage of phosphorylated SMAD1. (Con, 100±8.3%; WNT3, 133.8±33.8%; Con, 100±11.5%; and BMP7, 373.5±88.9% (n=3).
Data represent the mean ± s.e.m.: *p<0.05, **p<0.01, ***p<0.001. NS, not significant.
doi: 10.1371/journal.pone.0081769.g003
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Thymidine incorporation relative to levels observed in controls
treated with SHH alone (Figure 2C). This suggests that WNT3
is a negative regulator of GCP proliferation that can antagonize
the mitogenic action of SHH. Since SHH drives GCP
proliferation by inducing pro-proliferative genes that include
Gli1, Gli2, the D-type cyclins, and Mycn [23,70,71,72], we
measured the levels of the SHH-dependent transcriptional
targets Gli1, Gli2, Mycn, Ptch1, and Ccnd1 by qPCR (Figure
2D,E). The levels of Gli1, Gli2, and Ptch1 genes were
decreased after applying WNT3 to SHH treated GCPs (Figure
2E). Similar changes were seen in the presence of
cycloheximide, a protein synthesis inhibitor, suggesting that
down-regulation of these genes by WNT3 did not depend on
new protein synthesis (Figure S1B). These results suggest that
WNT3 inhibits GCP proliferation, at least in part, by down-
regulating the levels of a subset of SHH downstream target
genes.
To determine the level at which WNT3 impinges on the SHH
pathway, we examined whether WNT3 acts upstream or
downstream of the transcriptional regulator GLI1. We
electroporated GCPs with a pSR Gli1-expressing vector,
treated cells with control medium or WNT3, and examined the
mRNA transcript levels of Hh target genes by qPCR.
Overexpression of GLI1 in GCPs resulted in a 320 fold (± 119)
and 460 fold (± 166) increase in Gli1 transcript levels in the
control and WNT3 conditions, respectively. In addition,
overexpression of GLI1 increased the transcript levels of the
HH target genes Gli2 and Ptch1. In contrast, the transcript
levels of these target genes were not upregulated by GLI1
overexpression in the presence of WNT3 (Figure 2F),
confirming that WNT3 inhibits HH signaling at the level or
downstream of the transcriptional activator GLI1.
We next examined whether treatment with WNT3 affected
the expression level of markers for proliferating GCPs. In the
developing cerebellum, the bHLH transcription factor Atoh1 is
essential for GCP neurogenesis [73,74], and provides a marker
for proliferating GCPs. By qPCR, we observed that WNT3
down regulates the levels of Atoh1 (Figure 3A,B). To test
whether reduced expression levels of Atoh1 contribute to the
decreases in GCP proliferation we observed, we over-
expressed Atoh1 by retroviral infection (Figure S1C) and
assayed proliferation in the presence and absence of WNT3
with a [3H]-Thymidine incorporation assay. Over-expression of
ATOH1 suppressed the growth inhibition observed with WNT3
relative to results with a control retrovirus (Figure 3C). Thus,
the suppression of GCP proliferation by WNT3 involves down-
regulation of Atoh1. The mRNA expression of other mitotic
markers, Ki67 and Notch2, were also decreased with WNT3
treatment (Figure 3D).
To assess whether the decrease in GCP proliferation by
WNT3 is accompanied by an increase in differentiation, we
examined the expression of GCP differentiation markers in
WNT3 treated GCPs. We first examined the transcription factor
PAX6, which functions in cerebellar granule neuron
development [75,76,77] and serves as a marker for
differentiated GCPs. We used immunocytochemistry to
examine the effect of WNT3 treatment on the expression of
PAX6 in cerebellar slices (Figure 3E). These experiments
showed that WNT3 treatment, compared to control treatment,
increased the intensity of immunostaining with antibodies
against PAX6 in both the lower EGL, where GCPs are exiting
the cell cycle, and in the IGL, where post-migratory granule
neurons form synaptic connections with afferent mossy fibers.
In addition, intensely labeled PAX6 cells were located in the
molecular layer, where post-mitotic, differentiating GCPs
extend parallel fiber axons and migrate along Bergmann glial
processes. We also looked at the post-mitotic markers Zic2
and Gabra6 by qPCR, and found that the levels of these
differentiation markers also increased with WNT3 expression
(Figure 3F). Taken together, these results suggest that WNT3
inhibits GCP proliferation and promotes differentiation.
Because BMP signaling pathways play a critical role in GCP
differentiation [66,78,79], we next examined whether the GCP
growth suppression of WNT3 involved BMP signaling. In
agreement with prior studies, BMP2, BMP4, BMP6 and BMP7
inhibited [3H]-Thymidine incorporation (Figure 4A), and the
addition of WNT3 further inhibited GCP [3H]-Thymidine
incorporation (Figure 4A). The addition of the BMP antagonist
Noggin did not alter WNT3-induced inhibition of GCP
proliferation (Figure 4B), suggesting that WNT3 inhibition of
GCP proliferation is independent of BMP signaling. To further
examine whether WNT3 treatment activates BMP signaling, we
assayed SMAD phosphorylation in GCPs treated with WNT3 or
BMP7. Although treating GCPs with BMP7 triggered robust
SMAD phosphorylation, no significant changes in SMAD
phosphorylation occurred in GCPs treated with WNT3 (Figure
4C). These results suggest that inhibition of GCP growth by
WNT3 is independent of BMP signaling.
WNT3 suppresses medulloblastoma formation in a
mouse model
Because WNT3 decreased GCP proliferation, we tested
whether WNT3 also affected the formation of medulloblastoma
in two mouse models. GCP-like tumor cells were purified from
tumors that spontaneously arose in Ink4c-/-, p53Fl/-, Nestin-cre+
and Ink4c-/-, Ptch1+/- mice [23] and cultured for 3 days in the
presence or absence of WNT3. Cells showed decreased
growth in the presence of WNT3 (Control, 7.7±0.3x105 cells
and WNT3-treated, 3.8±0.3x105 cells; Figure 5A). After
treatment with WNT3, no increase in apoptosis was observed
using Annexin V (data not shown). FACS analysis revealed a
reduced number of cells in S phase (Figure 5B). When GCP-
like tumor cells were incubated with WNT3, we noted increased
expression of TAG1 and TUJ1, markers of differentiation
(Figure S2). To assess whether WNT3 suppresses tumor
growth in vivo, we infected tumor cells with retroviruses
expressing YFP alone or WNT3 and YFP (WNT3-YFP) and
injected them sub-cutaneously in the flank of athymic nude
mice. Tumors derived from cells expressing WNT3-YFP were
smaller than the tumors derived from cells expressing YFP
alone (Figure 5C, bottom right image panel and top right
graph). WNT3 YFP-expressing tumors also contained a
reduced number of YFP positive cells, suggesting that the
decrease in tumor growth was due to a decrease in
proliferation of WNT3-YFP infected cells (Figure 5C, top right
image panel and bottom right graph). Similar results were
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obtained when YFP positive cells selected by FACS were
injected into athymic nude mice, indicating that WNT3 inhibited
tumor growth (Figure 5D). To assess whether the inhibition of
tumor growth involved changes in the levels of proteins
important for GCP development, we assayed expression of
ATOH1. As observed with cerebellar GCPs, treatment of
medulloblastoma cells with WNT3 decreased the expression of
ATOH1 (Figure 5E). Thus WNT3 is a potent inhibitor of
medulloblastoma development.
WNT3 activates the MAPK/ERK1,2 and ERK5 signaling
pathway(s) in GCPs
To define the signaling pathways involved in WNT3 inhibition
of GCP and medulloblastoma growth, we examined whether
WNT3 activates the canonical WNT/β-catenin signaling
pathway. To investigate whether WNT3 affects β-catenin
activity in GCPs, we compared β-catenin activity in GCPs
treated with control or WNT3 to that in cells treated with the
GSK-3 inhibitor 6-bromoindirubin-3'-oxime (BIO) [80]. The
results of these experiments indicate that BIO, but not WNT3,
increased the amount of activated β-catenin in lysates of GCPs
(Figure 6A). In agreement with these findings, we found that
WNT3 treatment did not affect the levels of active, tyrosine-216
phosphorylated GSK-3β, nor did it induce expression of the
canonical WNT/β-catenin target MYCN in GCPs (Figure 6B).
Since β-catenin interacts with TCF/LEF to control transcription,
we also examined canonical WNT/β-catenin activity using a
luciferase assay, in which we expressed pTOPflash luciferase
Figure 3.  WNT3 decreases the GCP proliferation marker Atoh1 and increases the GCP differentiation marker PAX6.  (A)
WNT3 decreased Atoh1 mRNA levels after 6 h of treatment (Con=1; WNT3: Atoh1=0.52±0.06). (B) Treatment of GCPs with WNT3
decreased Atoh1 mRNA levels in the presence of SHH. SHH was added for 24 h and WNT3 was added for 6h. (SHH/Con=1; SHH/
WNT3: Atoh1=0.47±0.04). (C) Overexpression of ATOH1 by retroviral infection of GCPs abrogated the WNT3 effect as measured
by [3H]-Thymidine incorporation assay. GCPs were infected with retroviruses produced using pMSCV-GFP and pMSCV-Atoh1-GFP
on day 1. WNT3 was added to the GCPs on day 2. (GFP/Con, 100±2.5%; GFP/WNT3, 77.4±3.3%; ATOH1-GFP/Con, 98.9±2.3%;
ATOH1-GFP/WNT3, 92.6±3.8% (n=3).) (D) WNT3 decreased the mRNA levels of additional mitotic markers Ki67 and Notch2 after
24 h of treatment (Con=1; WNT3: Atoh1=0.71±0.07, Ki67=0.70±0.08, and Notch2=0.70±0.06). (E) P7 cerebellar slices were
incubated with WNT3 for 24 h, and cryostat sections were immunostained with anti-PAX6 antibody, a marker for GCP
differentiation. In control cultures (top panel), low levels of immunostaining are seen with anti-PAX6 antibody. WNT3 treatment
(lower panel) increases the intensity of anti-PAX6 immunostaining in GCPs in the external granule layer (EGL), in postmitotic GCPs
migrating across the molecular layer (ML, arrow) and in granule neurons in the internal granular layer (IGL) undergoing terminal
differentiation. (F) WNT3 increased the mRNA levels of additional post-mitotic markers Zic2 and Gabra6 after 24 h of treatment
(Con=1; WNT3: Zic2=3.22±0.54 and Gabra6=24.40±2.08). Data represent the mean ± s.e.m.: *p<0.05, **p<0.01, ***p<0.001. NS,
not significant. Scale bar 100 µm.
doi: 10.1371/journal.pone.0081769.g004
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driven by the TCF/LEF promoter. pTOPflash luciferase activity
did not increase after treatment of GCPs with WNT3 compared
to the control (Figure 6C and Figure S3A), suggesting that
WNT3 does not activate canonical WNT/β-catenin signaling in
GCPs.
Because WNT3 did not activate canonical, β-catenin-
dependent signaling in GCPs, we investigated the effect of
WNT3 on non-canonical signaling pathways. Mammalian
MAPKs are serine/threonine-specific protein kinases that
respond to extracellular stimuli and regulate various cellular
activities important for brain development [81,82]. MAPKs
include ERK1/2, ERK5, p38 and JNK. To determine whether
WNT3 activates any of these MAPKs, we treated GCPs with
WNT3 for 0-24 h and assessed the phosphorylation of the
MAPKs ERK1/2, ERK5, p38 and JNK by immunoblotting
analysis. WNT3 treatment resulted in a rapid increase of P-
ERK1/2 that was sustained up to 24 h relative to levels in
untreated, control cells (Figure 7A and Figure S3B). We infer
from these data that basal levels of ERK1/2 activation occur in
proliferating GCPs and that changes in the intensity and
duration of ERK1/2 activation induced by WNT3 shifted the
cells toward differentiation. Similarly, very low levels of P-ERK5
detected in the control GCP population were also vastly
increased by WNT3 treatment of GCPs (Figure 7A and Figure
S3B). In contrast, WNT3 treatment did not increase the levels
of P-p38 and P-JNK, compared to the control condition (Figure
Figure 5.  WNT3 inhibits murine medulloblastoma formation.  (A) (Left panels) GCP-like tumor cells treated with WNT3 for 3
DIV. (Right panel) Quantitation of total cell number. (Day 0, Con and WNT3, 3.5x105 cells; Day 3, Con, 7.7±0.3x105 cells and
WNT3, 3.8±0.3x105 cells (n=5).) Scale bar 50 µm. (B) Cell cycle analysis by FACS of GCP-like tumor cells treated with WNT3 for 72
h. (Ink4c-/-Ptc1+/- tumor, Con, 11±1.4% and WNT3, 6±0% (n=2) and Ink4c-/-p53Fl/-Nestin-cre+ tumor, Con, 24.5±2.12%, and WNT3,
12.5±2.12% (n=2).) After treatment with WNT3, no increase in apoptosis was observed using Annexin V (data not shown). (C)
(Right image panels) Image of allografts established from medulloblastoma cells of a mouse (Ink4c-/-p53Fl/-Nestin-cre+) infected with
control virus expressing YFP only or with virus expressing WNT3 and YFP. (Top right graph) Weight of allografts derived from cells
infected with control YFP (0.82±0.16 g) or with WNT3 and YFP (0.30±0.13 g) (n=4). (Bottom right graph) Analysis by FACS of YFP
expression in allografts derived from cells infected with control YFP (19.7±4.1%) or with WNT3 and YFP (2.9±1.2%) (n=3). (D)
Tumors from athymic mice bearing allograft from FACS-sorted YFP-positive tumor cells infected with control virus (top panel, YFP)
or WNT3 (bottom panel, WNT3-YFP), (n=2). (E) ATOH1 protein was decreased in WNT3 treated GCP-like tumor cells. Cyclopamine
was used as a postitive control. β-actin was used as a loading control. Data represent the mean ± s.e.m.: *p<0.05, **p<0.01,
***p<0.001. NS, not significant.
doi: 10.1371/journal.pone.0081769.g005
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7B). These results suggest that WNT3 activates ERK1/2 and
ERK5, but does not increase the levels of P-p38 or P-JNK in
GCPs, relative to controls.
To corroborate that WNT3 treatment activated MAPK/ERK
signaling, we used a plasmid with Firefly luciferase expression
controlled by a minimal promoter containing multiple serum
response factor (SRE) binding sites (Figure 7C). After
incubating GCPs with WNT3 for 24 h, luciferase expression
increased 1.5 ± 0.14 fold compared to control. BDNF was
included as a positive control, as it has been shown to increase
MAPK/ERK signaling. Notably, the newly commercially
available recombinant WNT3 protein described above
increased SRE luciferase activity, but not pTOPflash luciferase
activity, similar to our WNT3 conditioned medium (Figure
S4B,C).
To determine whether MAPK mediates the inhibitory effect of
WNT3 on GCP proliferation, we inhibited MAPK activity using
the MEK inhibitor PD98059. We first tested the efficacy of the
inhibitor using the Firefly luciferase controlled by a minimal
promoter with multiple SRE binding sites. After incubating
GCPs with PD98059 for 24 h, endogenous MAPK activity was
decreased compared to the control condition, and the increase
in MAPK activity induced by WNT3 was completely inhibited
(Figure 7D). Next, we treated GCPs with PD98059 for 24 h and
measured proliferation by [3H]-thymidine incorporation. While
treatment of GCPs with PD98059 only increased GCP
proliferation slightly in the control condition, the MEK inhibitor
totally reversed the inhibitory effect of WNT3 on GCP
proliferation (Figure 7E). These results confirm that WNT3
inhibits GCP proliferation via activation of MAPK signaling.
WNT3 activates the MAPK/ERK signaling pathway(s) ex
vivo in cerebellar organotypic slices and in
medulloblastoma cells
P-ERK1/2 expression in P7 cerebellar cortex is highest in the
inner aspect of the EGL, where GCPs exit the cell cycle and
undergo differentiation (data not shown). To examine whether
WNT3 treatment increased the phosphorylation of ERK1/2 ex
vivo, we treated organotypic slices of P7 cerebellum with
control or WNT3 for 24 h and assayed the levels of P-ERK1/2
immunostaining. WNT3 treatment increased the intensity of
immunostaining with anti-P-ERK1/2 antibodies in the cytoplasm
of GCPs located in the lower aspect of the EGL, a zone where
GCPs differentiate, and in the ML where postmitotic GCPs
migrate along Bergmann glial fibers (Figure 8A). These results
indicate that WNT3 treatment activated MAPK/ERK signaling in
GCPs located in zones where cells are exiting the cell cycle
and differentiating.
To examine whether WNT3 treatment activated ERKs in a
mouse model of medulloblastoma, we measured P-ERK levels
in purified tumor cells cultured for 24 h with WNT3 by
immunoblotting and immunolabeling. Immunoblotting showed a
marked increase in P-ERK1/2 and P-ERK5 levels with WNT3
treatment in medulloblastoma cells (Figure 8B,C).
Immunolabeling with anti-P-ERK1/2 antibodies further showed
that WNT3 treatment increased P-ERK1/2 in medulloblastoma
cells (Figure 8D). These results highlight a common
mechanism for inhibiting cell proliferation in normal CNS
progenitors and in CNS neural tumors.
Figure 6.  WNT3 signaling is not mediated by β-catenin signaling.  (A, B,) GCPs were treated with WNT3 for 24 h and lysates
analyzed by Western blot analysis. (A) Immunoblotting of GCP lysates with anti-active-β-catenin (Ac-β-cat) antibody showed that
WNT3 did not induce β-catenin activation. The GSK-3 inhibitor BIO was used as positive control to increase activated β-catenin and
activated β-catenin levels were compared to total β-catenin levels, using anti-β-catenin antibody (n=3). (B) Immunoblotting using
anti-Phospho(P)-216-GSK-3β, anti-GSK-3β and anti-MYCN antibodies showed that WNT3 does not regulate β-catenin signaling.
GAPDH was used as loading control. (C) Using a Luciferase assay, WNT3 fails to activate β-catenin signaling, which is reported by
the expression of pTOPflash luciferase driven by the TCF/LEF promoter. LiCl was used as a positive control to activate β-catenin
signaling. Data represent the mean ± s.e.m.: *p<0.05, **p<0.01, ***p<0.001. NS, not significant.
doi: 10.1371/journal.pone.0081769.g006
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Discussion
The present study identifies WNT3 as a novel extracellular
regulator of GCP proliferation and differentiation during normal
mouse cerebellar development, and as an inhibitor of tumor
growth in a mouse model of medulloblastoma. WNT3-treatment
inhibited GCP proliferation and antagonized the mitogenic
growth stimulation of SHH by down-regulating SHH pathway
components and the bHLH transcription factor Atoh1, which is
highly expressed in proliferating GCPs. GCP growth
suppression of WNT3 occurs through a non-canonical WNT
pathway that activates MAPK ERK1/2 and ERK5 signaling
(Figure 9). Importantly, WNT3 also suppressed
medulloblastoma growth in vivo in a mouse model of
medulloblastoma through mechanisms that involve activation of
ERK1/2 and ERK5 signaling.
Figure 7.  WNT3 activates the MAPK/ERK1,2 and ERK5 signaling pathway(s) in GCPs.  (A,B) GCPs were treated with WNT3
for 24 h and lysates analyzed by Western blot analysis. (A) WNT3 increases ERK1/2 and ERK5 phosphorylation in GCPs. Protein
extracts were analyzed by immunoblotting with anti-P-ERK1/2, anti-ERK1/2, anti-P-ERK5, and anti-ERK5 antibodies (n=3). GAPDH
was used as loading control. (B) Immunoblotting using anti-P-p38, anti-p38, anti-P-JNK and anti-JNK antibodies showed that WNT3
did not alter p38 or JNK activity. GAPDH was used as loading control. (C) Test of WNT3 specificity using a SRE Luciferase assay in
GCPs. BDNF was used as a positive control regulator of MAPK signaling (n=3). (D) MAPK activity induced by WNT3 in GCPs is
inhibited by the MEK inhibitor PD98059. SRE-luciferase assay in GCPs treated with control or WNT3, in the absence or presence of
PD98059 (n=3). (E). The MEK inhibitor PD98059 reverses WNT3 inhibition of GCP proliferation. As measured by [3H]-Thymidine
incorporation, PD98059 increases GCP proliferation by 15%±7%, WNT3 inhibits GCPs proliferation by 34±12% and PD98059 +
WNT3 inhibits GCP proliferation by 7%±5% of the control (Con) (n=3). Data represent the mean ± s.e.m.: *p<0.05, **p<0.01,
***p<0.001. NS, not significant.
doi: 10.1371/journal.pone.0081769.g007
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In many organisms, Wnt3 is expressed in the dorsal neural
tube. In mouse, Wnt3 is expressed in the dorsal part of the
spinal cord, parts of the diencephalon, the dorsal thalamus, the
midbrain-hindbrain region, dorsal ectoderm, branchial arches,
limb buds, and differentiating motor neurons [83,84,85,86,87].
Although highly similar in sequence, WNT3 and WNT3a have
been reported to play different roles during development
[88,89], and a loss of function mutation of Wnt3 cannot be
Figure 8.  WNT3 induces activation of ERK1/2 ex vivo in P7 cerebellar slices and in medulloblastoma cells.  (A) P7
cerebellar slices were incubated with WNT3 for 24 h, and cryostat sections were immunostained with anti-P-ERK1/2 antibodies.
Nuclei were stained with DRAQ5. P-ERK1/2 was induced in the external granule layer (EGL), and localized in the cytoplasm of the
GCPs in the lower aspect of the EGL, where GCPs commence differentiation. P-ERK1/2 was also located in the molecular layer
(ML) where postmitotic GCPs migrate toward the internal granule layer (IGL). Arrows point to an individual cell in the ML to highlight
the cytoplasmic localization of P-ERK1/2. Scale bar 20 µm. (B C, D) GCP-like tumor cells were treated 24 h with WNT3. After
treatment, GCP-like tumors were lysed and analysed by immunoblotting using (B) anti-P-ERK1/2 and anti-ERK1/2 antibodies or (C)
anti-P-ERK5 and anti-ERK5 antibodies. β-ACTIN was used as loading control. (D) GCP-like tumor cells were immunostained after
treatment using anti-P-ERK1/2 antibodies. Nuclei were stained with DRAQ5. WNT3 treatment increased the number of GCP-like
tumor cells containing cytoplasmic P-ERK1/2, compared to the control. Scale bar 20 µm.
doi: 10.1371/journal.pone.0081769.g008
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rescued by Wnt3a [90]. Our analysis of Wnt3 gene expression
indicated that Wnt3 mRNA, but not Wnt3a, is expressed in the
developing cerebellum (Figure 1A), and WNT3 protein levels
increase during the first two post-natal weeks (Figure 1B). Our
results are in agreement with a prior study that reported
expression of Wnt3 by Purkinje neurons [91], which appear at
E16.5 and mature postnatally when cerebellar granule cells exit
the cell cycle and differentiate. Thus the timing of Purkinje
neuron maturation, WNT3 expression, and GCP differentiation
support the view that WNT3 inhibits GCP proliferation and
promotes differentiation. Interestingly, SHH is also produced by
Purkinje cells [1], but levels of SHH signaling components tend
to decrease as cerebellar granule cells exit the cell cycle and
differentiate (Figure S5). The differential expression profiles of
WNT3 and SHH signaling components suggest that these
signaling pathways contribute to the balance between GCP
proliferation and differentiation during GCP development.
The present study indicates that WNT3 antagonizes SHH
signaling by down-regulating pro-proliferative SHH target
genes and shifts the GCP population toward differentiation,
consistent with previous studies showing that WNT3 attenuates
SHH signaling during chick neural tube patterning [85].
However, the ability of WNT3 to down-regulate a subset of
SHH target genes, namely Gli1, Gli2, and Ptch1, but not Ccnd1
or Mycn (Figure 2D,E), suggests that the effect of WNT3 on
GCP growth is not merely due to an effect on proliferation, and
could reflect context dependent, combinatorial regulation of
Gli1-3 transcription factors and the contribution of other
signaling pathways [92]. The growth inhibition of GCPs by
WNT3 and decrease in SHH target genes is accompanied by a
decrease in the transcription factor Atoh1 (Figure 3A,B), a
marker for proliferating GCPs, and an increase in the
expression of the GCP differentiation marker PAX6 (Figure
3D), suggesting that WNT3 decreases GCP proliferation while
promoting differentiation. While the extent of GCP growth
inhibition that we observed with WNT3 (Figure 2A) is
comparable to the level of inhibition reported for BMPs (Figure
4A) [66,79], WNT3 inhibits GCP growth independent of BMP
signaling. This conclusion is based on our findings that the
BMP antagonist Noggin did not alter WNT3-induced inhibition
of GCP proliferation (Figure 4B) and WNT3 treatment did not
activate SMAD signaling in the GCP population (Figure 4C).
Notably, the degree of GCP growth inhibition that we observed
with WNT3 (Figure 2A) is larger than the inhibition reported for
pituitary adenylate cyclase-activating polypeptide (PACAP)
[93], which also opposes the action of SHH signaling pathways
on GCPs [93]. Importantly, both WNT3 enriched from
conditioned medium and commercially available WNT3
decreased GCP proliferation and activated MAPK signaling
(Figure 2A, Figure 7C, and Figure S4 A,C). Taken together, the
results of the present study suggest that, in addition to
integrating signals from SHH and BMPs, proliferating GCPs
incorporate a WNT3 response to exit the cell cycle and begin to
differentiate into granule neurons. Thus, multiple pathways
control the remarkable expansion and differentiation of
cerebellar GCPs in the early postnatal period.
The non-canonical involvement of ERK signaling that we
observed for WNT3 underscores the complexity of GCP
Figure 9.  Interactions between WNT3 and SHH signaling pathways in GCPs.  In Hedgehog (Hh) signaling, Sonic Hedgehog
(SHH) binds Patched (PTCH) receptor, relieving its inhibition of Smoothened (SMO), and stimulating GCP proliferation. In WNT3
signaling, WNT3 binds an undefined receptor to activate MAPK signaling via a non canonical WNT pathway to promote GCP
differentiation, whereas other WNTs bind Frizzled (FRZ) receptor to activate the canonical β-catenin pathway and stimulate
proliferation. We propose a model whereby regulation of MAPK activity by WNT3 signaling alters the balance between proliferation
and differentiation in GCPs, decreasing proliferation and increasing differentiation.
doi: 10.1371/journal.pone.0081769.g009
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development that involves multiple cellular processes and
signaling pathways. We were initially surprised that WNT3
inhibition of GCP proliferation and mouse medulloblastoma
formation involved activation of ERK1/2 and ERK5. However, a
number of recent studies have reported a requirement for
sustained ERK signaling in neuronal differentiation [94,95,96].
The MAPK/ERK signaling network coordinates inputs from
different growth factors to regulate growth versus
differentiation. Increasing evidence indicates that the role of
ERK signaling in differentiation versus proliferation depends on
the basal level of ERK activation, the nature of the stimulus and
the duration of ERK activation. In PC12 cells, EGF and NGF
shape MAPK network topology differently, eliciting positive or
negative feedback loops and, in some cases, reversing specific
responses to EGF or NGF [81]. Thus, the MAPK network in
GCPs is likely to depend on growth factor context, with WNT3
as a novel MAPK regulator triggering sustained ERK signaling
to induce cell cycle exit and/or differentiation. In GCPs, SHH
signaling promotes proliferation [1], while WNT3 inhibits SHH
transcriptional responses at the level of or downstream of the
transcriptional activator GLI1 (Figure 2F), suggesting that a
balance between these pathways determines whether cells will
proliferate or differentiate (Figure 9). Interestingly, ERK5 has
been implicated in the regulation of the pro-neural activities of
Neurogenin1 (Ngn1) in cortical progenitors [97], which is
consistent with our findings that P-ERK5 is present in GCPs
and is associated with the differentiation of these neurons.
These findings highlight the complicated nature of ERK
signaling, and their potential involvement in multiple stages of
GCP development and signaling pathways. Since the biological
actions of ERKs depend on the cell type, the strength of
stimulation, the duration of the signal and the subcellular
localization of P-ERK [81,98], the precise role(s) that the ERKs
play in GCP development will require further experimentation,
and will be difficult to tease apart.
At present, at least four families of proteins are thought to
function as WNT receptors. Members of the Frizzled (FZD)
protein family are well known for their ability to transduce
canonical WNT/β-catenin signaling. The LDL receptor-related
proteins, LRP-5 or LRP-6, act as co-receptors with FZD in
canonical WNT/β-catenin signaling, arguing against a role for
them in the effects of WNT3 on GCP proliferation [99,100,101].
The Receptor Tyrosine Kinase ROR2 acts as a receptor or co-
receptor for WNT2, WNT5 and WNT5a [102,103]. Since ROR2
is not expressed in developing cerebellum [104], it can be
excluded as a WNT3 receptor in cerebellar GCPs. The fourth
class of WNT receptors is the Related to Receptor Tyrosine
Kinase protein (RYK) [105,106,107]. Since RYK is expressed
at high levels in the EGL of the developing mouse cerebellum
(GENSAT project), where GCPs proliferate, exit the cell cycle,
and commence differentiation, it is a putative receptor for
WNT3 in cerebellar GCPs. Biochemical analyses of RYK as a
WNT3 receptor are complicated by the finding that WNT/RYK
signaling may require one of several co-receptors to promote
differentiation (e.g. Ephrin receptors (Ephs)) [105,108].
Noteworthy, RYK interacts with Src family kinases (SFKs)
[109], which contribute to Raf/ERK signaling. It is therefore
plausible that WNT3 activates the RYK receptor to signal
through a non-canonical Src/Raf/ERK pathway to modulate
SHH signaling and thus the balance between proliferation and
differentiation in developing GCPs [110,111]. Identification of
the receptor(s) and co-receptor(s) that WNT3 acts through to
regulate GCP proliferation and differentiation will provide
further information on the mechanism(s) regulating these
cellular processes.
These studies underscore the emerging view that the
developing cerebellum provides a crucial system for evaluating
molecular pathways that are important for the development of
medulloblastoma [8]. The external germinal layer (EGL) of the
early postnatal cerebellum is a complex structure that provides
a system for analyzing the balance between the multiple
pathways that govern the remarkable pace of GCP
proliferation, increasing approximately 30 fold between birth
and P15 (our unpublished observation), and induce cell cycle
exit and differentiation. Although the complexity of studying
cells in different stages of development poses technical
challenges, it is of critical importance to discovering
mechanisms of medulloblastoma formation, since subgroups of
medulloblastoma arise from defects in signaling pathways that
disrupt the normal balance of GCP growth and differentiation.
Our finding that WNT3 is a potent suppressor of GCP growth
and tumor formation in a mouse model of medulloblastoma
suggests that WNT3 may have potential therapeutic value for
the treatment of medulloblastoma in humans. Understanding
how WNT3 responses are integrated with mitogenic signaling
pathways, such as SHH and JAG1, and pathways that promote
differentiation in GCP development and medulloblastoma, can
be expected to provide critical insight on both normal cerebellar
development and the growth of human medulloblastomas.
Supporting Information
Figure S1.  (A) By Western blot analysis, a band with the
apparent molecular weight of WNT3 is detected in
conditioned medium collected from NIH 3T3 cells stably
transfected with the pCXi retrovirus containing Wnt3
cDNA, but not from control NIH 3T3 cells. (B) WNT3
decreased Gli1, Atoh1, and Patched1 (Ptch1) mRNA levels
following 6 h of WNT3 treatment in the presence of
cycloheximide (CHX). Control=1, WNT3: Gli1=0.72±0.10,
Gli2=0.93±0.05, Atoh1=0.62±0.08, Mycn=0.88±0.04,
Ptch1=0.66±0.09, and Ccnd1 =0.95±0.08. (C) Infection of
GCPs with ATOH1 expressing retrovirus for 48 h increases the
levels of ATOH1 2.06 fold over endogenous ATOH1 levels.
Data represent the mean ± s.e.m.: *p<0.05, **p<0.01,
***p<0.001. NS, not significant.
(TIF)
Figure S2.  WNT3 increased TAG1 and TUJ1 levels in GCP-
like tumor cells at 3 DIV. Scale bar 100 µm.
(TIF)
Figure S3.  WNT3 regulation of MAPK signaling. (A) Using a
Luciferase assay, MAPK signaling increases proportionally to
WNT3 concentration in GCPs, which is reported by the
expression of Firefly luciferase driven by the SRE promoter, but
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WNT3 fails to activate β-catenin signaling, which is reported by
the expression of pTOPflash luciferase driven by the TCF/LEF
promoter. (B) Activation of ERK1/2 and ERK5 in response to
WNT3 treatment in GCPs. ERK phosphorylation is rapidly
induced with WNT3 treatment. GCPs were treated with WNT3
for 0 to 6 h, and lysates were analyzed by Western blot
analysis, using anti-P-ERK1/2, ERK1/2, P-ERK5 and ERK5
antibodies. GAPDH was used as a loading control. (Bottom
panels) Quantification of P-ERK1/2 and P-ERK5 intensity
normalized to ERK1/2 and ERK5 signal, respectively, as a
function of time.
(TIF)
Figure S4.  Commercially available, recombinant WNT3
inhibits proliferation in GCPs and activates MAPK
signaling. (A) Commercially available WNT3 decreases GCP
proliferation by 18.6 ± 3.51% compared to the control (n=4) as
measured by [3H]-Thymidine incorporation assay. Statistical
significance of WNT3 or SHH is compared to control. (B) Using
a luciferase assay, commercially available WNT3 fails to
activate β-catenin signaling, which is reported by the
expression of pTOPflash luciferase driven by the TCF/LEF
promoter. CHIR99021 (136.53% ± 5.23% of control, n=3) is an
inhibitor of glycogen synthase kinase 3β (GSK3β) that
activates canonical WNT/β-catenin signaling, and was used as
a positive control to demonstrate that the canonical WNT
signaling pathway is functional in cultured GCPs. GCPs were
treated with 250 ng/ml of commercially available WNT3
(Creative Biomart) or 3 µM CHIR99021 (StemGent). (C) Test of
commercially available WNT3 specificity using an SRE
luciferase assay in GCPs. Commercially available WNT3
(167.04 ± 10.04% of control, n=3) activates MAPK signaling,
reported by the expression of Firefly luciferase driven by a
minimal MAPK promoter plus multiple SRE binding sites. Data
represent the mean ± s.e.m.: *p<0.05, **p<0.01, ***p<0.001.
NS, not significant.
(TIF)
Figure S5.  qPCR of SHH signaling components, including
Gli1, Gli2, Ptch1, Ptch2, Smo, Ccnd1, Mycn, and a
transcription factor expressed in proliferating GCPs,
Atoh1, in the mouse cerebellum from P5 to adult. SHH
signaling molecules and Atoh1 levels were normalized against
β-2-microglobulin (B2M), hyporanthine-guanine
phosphoribosyltransferase (HPRT1) and ribosomal subunit 18s
(M18s).
(TIF)
Table S1.  List of qPCR primers.
(DOCX)
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